REG - Coiled Therapeutics - Admission to Trading and First Day of Dealings
27/03/2026 08:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260327:nRSa3535Ya&default-theme=true
RNS Number : 3535Y Coiled Therapeutics PLC 27 March 2026
27 March 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Admission to Trading and First Day of Dealings
Clinical stage oncology company joins AIM
Coiled Therapeutics plc (AIM:COIL), previously called Roquefort Therapeutics
plc, is pleased to announce, in conjunction and simultaneously with the
completion of the acquisition of the exclusive worldwide licence to AO-252,
the admission of its ordinary shares to trading on the AIM Market of the
London Stock Exchange today at 8:00am ("Admission") under the ticker "COIL"
and an ISIN GB00BSHRN331.
Admission follows the successful Fundraise of £8.5 million (before expenses)
at 10 pence per New Ordinary Share through the issue of 85,000,000 New
Ordinary Share with institutional investors.
More information on Coiled Therapeutics and a copy of the Admission Document
can be found here: www.coiledplc.com (http://www.coiledplc.com) .
Highlights
· Successful transition from a pre-clinical platform to a material
clinical-stage oncology company focused on precision medicine.
· Lead asset AO-252 is a first-in-class, orally administered,
brain-penetrant small molecule inhibitor targeting TACC3, a validated
previously undruggable oncology target.
· Early Phase I data in advanced solid tumours is encouraging, having
already demonstrated tumour reductions of up to 33% in endometrial and 29% in
ovarian cancer patients at sub-therapeutic exposure levels.
· AO-252 has shown a favourable benign safety and tolerability profile
to date, contrasting positively with traditional forms of cancer treatment.
· Entry into the high value precision oncology market where comparable
approved therapies currently command a market size exceeding US$20 billion.
· Completion of the £8.5 million (gross) Fundraise provides the
capital runway to reach key clinical and value inflection points relating to
the development of AO-252 in 2026 and 2027.
· Strong backing from A2A Pharmaceuticals, Inc. ("A2A Pharma") and its
investor group, who have a proven track record of billion-dollar value
creation in the biotech sector.
· Expansion of the AO-252 Phase I trial into prostate and ovarian
cancers is underway, with material data readouts anticipated by Q4 2026
providing near term catalysts to support commercial discussions.
· Potential to advance directly from Phase I to registration grade
Phase II trial, expediting the route to market authorisation.
· In addition to AO-252, the Company is assessing its STAT-6 siRNA
programme for a Phase I clinical trials for immunology, providing a potential
dual asset pipeline.
· The Board and management team has deep expertise in drug discovery,
regulatory strategy, successful clinical and commercial execution.
Dr Sotirios Stergiopoulos, Executive Chairman of Coiled Therapeutics,
commented:
"We are delighted to have completed the transaction and to begin Coiled
Therapeutics' journey as an AIM quoted company. AO-252 is a first-in-class
asset that is already delivering encouraging signals of efficacy in patients
with advanced solid tumours who have exhausted all other treatment options.
The Fundraise will allow us to drive forward our dual indication strategy,
which prioritises the expansion of our Phase I trial into patients with
prostate and ovarian cancers. These are areas where patients face a major lack
of effective therapies after failing standard treatments. We believe AO-252's
unique ability to target TACC3 and cross the blood-brain barrier offers a
potential lifeline for these patients.
With the support of our new and existing shareholders, we have the necessary
capital to accelerate these programmes and generate the material data readouts
required to drive forward partnering discussions. By addressing these critical
unmet medical needs, we are focused on reaching the key clinical inflection
points that will drive our commercial strategy and create significant
long-term value for our shareholders."
Note
Capitalised terms which are not defined in this announcement have the same
meaning given to them in the Admission Document which was published on 2 March
2026.
Enquiries:
Coiled Therapeutics plc
Sotirios Stergiopoulos (Chairman) Via Burson Buchanan
Sridhar Vempati (CEO)
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) +44 (0)20 3470 0470
David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Shard Capital Partners LLP (Joint Broker) +44 (0)20 4530 6926
Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) +61 (0)8 9223 2222
Jason Peterson / David Valentino
Burson Buchanan (Public Relations) +44 (0)20 7466 5000
Henry Harrison Topham / Jamie Hooper / Toto Berger
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology
company focused on developing innovative precision oncology therapies. Its
lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I
clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is
actively enrolling patients to test for safety and efficacy in patients whose
cancer has progressed on other treatments. The Company is also assessing
its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is
supported by a leadership team with a proven track record in drug development
and strategic backing from A2A Pharmaceuticals.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small
molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3
(TACC3). TACC3 is a validated oncology target that is frequently overexpressed
in many aggressive, hard-to-treat solid tumours but is dispensable in normal
adult cells, providing a wide therapeutic window.
By selectively disrupting cancer-critical protein-protein interactions at the
TACC3 C-terminal domain, AO-252 induces mitotic and replication stress,
impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has
demonstrated the ability to cross the blood-brain barrier, addressing a
significant unmet medical need for the treatment of brain metastases.
The asset is currently in an ongoing Phase I open-label dose-escalation study
and early clinical signals have shown encouraging anti-tumour activity and a
benign safety profile, with the Company planning to initiate dose expansion
cohorts in lead indications, including prostate and ovarian cancer, during
2026.
For more information, please visit: www.coiledplc.com
(http://www.coiledplc.com/)
Board of Coiled Therapeutics plc
Dr. Sotirios Stergiopoulos, Executive Chairman
Dr. Stergiopoulos is a distinguished physician executive with extensive global
experience in the pharmaceutical and biotechnology industries, specifically
within oncology. He previously served as the Chief Medical Officer of Ipsen, a
multi-billion-dollar Euronext-listed pharmaceutical company. His clinical
background includes roles as an Attending Physician and trainee at prestigious
institutions, including the Albert Einstein College of Medicine, Harvard
Medical School, and the National Institutes of Health (NIH). He holds a
Medical Degree from Poznan University of Medical Sciences and a Master's in
Biotechnology Enterprise and Entrepreneurship (MBEE) from Johns Hopkins
University.
Sridhar Vempati, Chief Executive Officer
Mr. Vempati brings nearly 20 years of expertise in drug discovery, oncology
research, and business strategy. He has a proven track record of advancing
novel therapeutics from initial concept through to clinical development. In
2016, he co-founded A2A Pharma, where he served as Chief Strategy Officer and
oversaw the computational drug design platforms that discovered AO-252. His
earlier career includes roles in business development at Ironwood
Pharmaceuticals and Rafael Pharmaceuticals, as well as experience as an Equity
Research analyst at Jefferies LLC. He holds a PhD in molecular biology from
Ludwig-Maximilians-University, Germany, and an MBA from Boston University.
Jean Marie Duvall, Non-Executive Director
Ms. Duvall is a highly accomplished leader in the biopharma sector with over
25 years of experience. She was a key executive board member at Ferring
Pharmaceuticals during its growth from $700 million to $2 billion in revenue.
Her expertise spans corporate development, M&A, and legal affairs, having
previously served as General Counsel at Elan Corporation. She has co-founded
several biotech start-ups, including Trizell and Amzell, which have
successfully moved products through Phase II and Phase III clinical trials.
She is currently the CEO of ReproNovo SA.
Pamela Frank, Non-Executive Director
Ms. Frank is an expert in strategic coalition building and regulatory advocacy
with over 30 years of experience. She currently serves as Senior VP at Gabel
Associates and CEO of ChargEVC, a non-profit focused on sustainable energy.
She has a strong background in public health and policy development, having
served on various advisory councils for the Governor of New Jersey. She holds
a Master of Public Health (MPH) from the University of Medicine &
Dentistry of New Jersey and brings a wealth of experience in navigating
complex multi-stakeholder environments and governance.
Stephen West, Non-Executive Director
Mr. West is a Fellow Chartered Accountant with over 30 years of experience in
international financial, corporate, and public company management. He was a
co-founder of Roquefort Therapeutics plc and has held senior executive and
board positions across several sectors, including life sciences and natural
resources. Notably, he was instrumental in the $100 million merger of African
Petroleum Corporation and PetroNor E&P.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFQLLLQXLXBBB
Copyright 2019 Regulatory News Service, all rights reserved